Clovis Oncology Inc (NASDAQ:CLVS) rocketed almost 50% as its trial for advanced ovarian cancer treatment rucaparib passed its final stage with flying colours.
A treatment for women with platinum-sensitive ovarian cancer, rucaparib demonstrated improved progression free survival (PFS) in all three indications while it also improved PFS in a blind independent review, which was the secondary endpoint.
Clovis added it will now submit a New Drug Application within the next four months for a second-line and later maintenance treatment indication for all women with platinum-sensitive ovarian cancer who responded to their most recent platinum therapy.
“We are very pleased with these positive ARIEL3 topline results that strongly demonstrate the potential of rucaparib to help women with platinum-sensitive, advanced ovarian cancer,” said
“These results reinforce the potentially foundational role of rucaparib in the management of advanced ovarian cancer, as demonstrated by both investigator review and the blinded independent central review.”
Shares rose US$27.91 to US$87.88, valuing the group at US$3.95bn.